We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Justice Department has launched a formal probe into Pfizer’s sales practices for two products that account for more than $1 billion in annual U.S. sales, the firm has announced in a regulatory filing.
Pennsylvania has joined the growing list of states that are suing drugmakers for deceptive reporting of average wholesale prices (AWPs), inflating Medicaid and Medicare reimbursements and marketing the price spread to physicians to increase market share.
A federal district court in Maine late Tuesday issued a preliminary injunction blocking a Maine law that would have designated pharmaceutical benefit managers (PBMs) as fiduciaries, requiring them to disclose proprietary pricing information negotiated with drugmakers.
The Ohio attorney general has targeted Pfizer’s Pharmacia unit and several other drugmakers in a lawsuit that alleges the companies reported false average wholesale price (AWP) data to inflate Medicare and Medicaid reimbursements for prescription drugs.
As momentum builds toward pushing reimportation legislation through Congress this year, pharmaceutical industry representatives are actively trying to refocus the debate about drug pricing.
The FDA cannot accept Minnesota Gov. Tim Pawlenty’s invitation to inspect the operation of its drug reimportation website, according to a high-ranking agency official. “The FDA does not have the legal authority to engage in the sort of test program that Gov. Pawlenty is proposing,” William Hubbard, the FDA’s associate commissioner for policy and planning, told WDL last week.
A class action lawsuit alleging 20 drug manufacturers overstated their average wholesale prices (AWPs) and inflated Medicare and other third-party payments for prescription drugs by engaging in fraud, kickbacks and conspiracy can proceed, a federal district judge in Boston has ruled.
Despite what critics charge, drug manufacturers say they won't reap billions of dollars in additional profits under the new Medicare prescription drug law and contend the benefit will have little overall effect on revenues or research and development efforts.
A federal district judge in Boston has refused to dismiss a class action lawsuit alleging that 20 drug manufacturers overstated their average wholesale prices (AWPs) and inflated Medicare and other third-party payments for prescription drugs by engaging in fraud, kickbacks and conspiracy.